CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $6.26B, above the global median of $1.18B
- PositionOperating margin is 49.8%, higher than 95% of its Biotechnology peers (median -24.1%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.26BUSDvs all stocks (USD)
Trailing P/E
50.25xvs Biotechnology peers
Revenue (TTM)
450.91MUSDvs all stocks (USD)
Profit Margin
30.74%vs Biotechnology peers
Beta
0.5720xvs all stocks
52-Week Change
154.70%vs all stocks
Market Capitalization
6.26BUSDvs all stocks (USD)
Enterprise Value
6.29BUSDvs all stocks (USD)
Trailing P/E
50.25xvs Biotechnology peers
Forward P/E
12.63xvs Biotechnology peers
PEG Ratio
-0.2154xvs Biotechnology peers
Price to Sales (TTM)
14.17xvs Biotechnology peers
Price to Book (MRQ)
32.58xvs Biotechnology peers
Enterprise to Revenue
13.94xvs Biotechnology peers
Enterprise to EBITDA
37.03xvs Biotechnology peers
Gross Margin
91.08%vs Biotechnology peers
Profit Margin
30.74%vs Biotechnology peers
Operating Margin
49.81%vs Biotechnology peers
Return on Assets (TTM)
27.04%vs Biotechnology peers
Return on Equity (TTM)
131.82%vs Biotechnology peers
Revenue (TTM)
450.91MUSDvs all stocks (USD)
Revenue per Share (TTM)
5.15USDUpdated Aug 28, 2026Quarterly Revenue Growth
1842.70%vs Biotechnology peers
Gross Profit (TTM)
417.28MUSDvs all stocks (USD)
EBITDA (TTM)
169.77MUSDvs all stocks (USD)
Net Income (TTM)
138.61MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
4158.49%vs Biotechnology peers
Operating Cash Flow (TTM)
167.71MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
74.30MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Revenue
158.32MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
13.24MUSDFY2025 · Dec 31, 2025Gross Profit
145.08MUSDFY2025 · Dec 31, 2025Operating Income
-51.38MUSDvs all stocks (USD)
Pre-tax Income
-68.92MUSDFY2025 · Dec 31, 2025Net Income
-68.92MUSDFY2025 · Dec 31, 2025EBIT
-44.75MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-43.22MUSDFY2025 · Dec 31, 2025Research & Development
39.28MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
157.18MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
6.62MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
24.17MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-68.92MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-91.08MUSDFY2025 · Dec 31, 2025Free Cash Flow
-95.41MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
194.18MUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-68.92MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.53MUSDFY2025 · Dec 31, 2025Stock-based Compensation
29.47MUSDFY2025 · Dec 31, 2025Other Non-cash Items
26.41MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-51.37MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-2.59MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-25.59MUSDFY2025 · Dec 31, 2025Capital Expenditures
-4.34MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-2.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-4.34MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
74.97MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-21.15MUSDFY2025 · Dec 31, 2025Other Financing Charges
1.08MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
54.91MUSDFY2025 · Dec 31, 2025Shares Outstanding
88.31MSharesUpdated Aug 28, 2026Float Shares
63.27MSharesUpdated Aug 28, 2026Shares Short
11.86MSharesUpdated Aug 28, 2026Short Ratio
7.42daysvs all stocks
Short % of Shares Outstanding
16.43%vs all stocks
% Held by Insiders
12.55%vs all stocks
% Held by Institutions
81.95%vs all stocks
Total Cash (MRQ)
284.18MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.17USDUpdated Aug 28, 2026Total Debt (MRQ)
182.90MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.9374xvs Biotechnology peers
Current Ratio (MRQ)
2.31xvs Biotechnology peers
Book Value per Share (MRQ)
2.19USDUpdated Aug 28, 2026Total Assets
327.93MUSDvs all stocks (USD)
Total Current Assets
273.40MUSDFY2025 · Dec 31, 2025Total Liabilities
283.19MUSDFY2025 · Dec 31, 2025Total Non-current Assets
54.53MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
147.42MUSDFY2025 · Dec 31, 2025Total Current Liabilities
135.77MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
190.68MUSDFY2025 · Dec 31, 2025Accounts Receivable
54.09MUSDFY2025 · Dec 31, 2025Inventory
23.80MUSDFY2025 · Dec 31, 2025Accounts Payable
3.68MUSDFY2025 · Dec 31, 2025Short-term Debt
58.89MUSDFY2025 · Dec 31, 2025Long-term Debt
139.03MUSDFY2025 · Dec 31, 2025Common Stock (Book)
87.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-626.31MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
44.75MUSDvs all stocks (USD)
52-Week Low
21.15USDUpdated Aug 28, 202652-Week High
93.61USDUpdated Aug 28, 202652-Week Change
154.70%vs all stocks
Beta
0.5720xvs all stocks
50-Day MA
79.09USDUpdated Aug 28, 2026200-Day MA
49.92USDUpdated Aug 28, 2026Avg 10-Day Volume
1.73MSharesUpdated Aug 28, 2026Avg 30-Day Volume
1.56MSharesUpdated Aug 28, 2026Diluted EPS (TTM)
1.42USDUpdated Aug 28, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 49.8%, higher than 95% of its Biotechnology peers (median -24.1%)Significant
Operating margin: 0.50Industry median: -0.24Industry P95: 0.38Peers compared: 194
Return on equity is 131.8%, higher than 95% of its Biotechnology peers (median -23.6%)Significant
Return on equity: 1.32Industry median: -0.24Industry P95: 0.23Peers compared: 194
Return on assets is 27%, higher than 95% of its Biotechnology peers (median -21.3%)Significant
Return on assets: 0.27Industry median: -0.21Industry P95: 0.19Peers compared: 194
Financial Health
Altman Z-Score 11.13: safe zoneNotable
Altman Z-Score: 11.13
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $6.26B, above the global median of $1.18BNotable
Market cap (USD): 6,260,251,836Global Median: 1,179,398,897.704
Levered free cash flow is $74.3M, above the global median of $19.19MNotable
Levered free cash flow (USD): 74,296,128Global Median: 19,189,974.917
Companies that share the same coordination system — how they create, deliver, or capture value.
Shenzhen New Industries Biomedical Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Amneal Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Travere Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kiniksa Pharmaceuticals International, plc
Tier 1ProductionApproval-Gated PipelineRule
Dianthus Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sunshine Guojian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sectra AB
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Cogent Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Oruka Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
H. Lundbeck A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow